Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
P/B ratio for Repare Therapeutics Inc. (RPTX)
P/B ratio as of 2023: 1.45
According to Repare Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.45. At the end of 2022 the company had a P/B ratio of 2.21.
P/B ratio history for Repare Therapeutics Inc. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.45 |
| 2022 | 2.21 |
| 2021 | 2.77 |
| 2020 | 4.41 |
| 2019 | -24.48 |
| 2018 | -21.73 |
| 2017 | 0.00 |